Tafinlar (dabrafenib)

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

BRAF inhibitor

Related drugs:

BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) trametinib + dabrafenib Sensitive : A1 ASCO 2023 - 1wk	trametinib + dabrafenib Sensitive: A1 - Approval ASCO 2023 - 1 week trametinib + dabrafenib Sensitive : A1 ASCO 2023 - 1 week - (New C3)
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) trametinib + dabrafenib Sensitive : A1 ASCO 2023 - 1wk	trametinib + dabrafenib Sensitive: A1 - Approval ASCO 2023 - 1 week trametinib + dabrafenib Sensitive : A1 ASCO 2023 - 1 week - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) trametinib + dabrafenib Sensitive : A1 ASCO 2023 - 1wk	trametinib + dabrafenib Sensitive: A1 - Approval ASCO 2023 - 1 week trametinib + dabrafenib Sensitive : A1 ASCO 2023 - 1 week - (New C3)
BRAF mutation	Melanoma	BRAF mutation	Melanoma	trametinib + dabrafenib + ABT 263 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) trametinib + dabrafenib + ABT 263 Sensitive : C3 ASCO 2023 - 1wk	trametinib + dabrafenib + ABT 263 Sensitive: C3 – Early Trials ASCO 2023 - 1 week trametinib + dabrafenib + ABT 263 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
BRAF mutation	Melanoma	BRAF mutation	Melanoma	dabrafenib + ivosidenib Sensitive: D – Preclinical ASCO 2023 - 1 week (New D) dabrafenib + ivosidenib Sensitive : D ASCO 2023 - 1wk	dabrafenib + ivosidenib Sensitive: D – Preclinical ASCO 2023 - 1 week dabrafenib + ivosidenib Sensitive : D ASCO 2023 - 1 week - (New D)
BRAF V600	Non Small Cell Lung Cancer	BRAF V600	Non Small Cell Lung Cancer	trametinib + dabrafenib Sensitive: A1 - Approval Precision Oncology News - 3 weeks (New A2) trametinib + dabrafenib Sensitive : A1 Precision Oncology News - 3wk	trametinib + dabrafenib Sensitive: A1 - Approval Precision Oncology News - 3 weeks trametinib + dabrafenib Sensitive : A1 Precision Oncology News - 3 weeks - (New A2)
BRAF V600E	Melanoma	BRAF V600E	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
BRAF V600E	Solid Tumor	BRAF V600E	Solid Tumor	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Glioma	BRAF V600E	Glioma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Neuroendocrine Tumor	BRAF V600E	Neuroendocrine Tumor	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Biliary Tract Cancer	BRAF V600E	Biliary Tract Cancer	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600K	Cutaneous Melanoma	BRAF V600K	Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	trametinib + dabrafenib + panitumumab Sensitive: A2 - Guideline trametinib + dabrafenib + panitumumab Sensitive : A2	trametinib + dabrafenib + panitumumab Sensitive: A2 - Guideline trametinib + dabrafenib + panitumumab Sensitive : A2
BRAF V600K	Melanoma	BRAF V600K	Melanoma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline cetuximab + trametinib + dabrafenib Sensitive : A2	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline cetuximab + trametinib + dabrafenib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	pembrolizumab + dabrafenib Sensitive: A2 - Guideline pembrolizumab + dabrafenib Sensitive : A2	pembrolizumab + dabrafenib Sensitive: A2 - Guideline pembrolizumab + dabrafenib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2	dabrafenib Sensitive: A2 - Guideline dabrafenib Sensitive : A2
BRAF V600E	Ovarian Serous Adenocarcinoma	BRAF V600E	Ovarian Serous Adenocarcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH2 mutation + BRAF V600E	Astrocytoma	IDH2 mutation + BRAF V600E	Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH1 mutation + BRAF V600E	Astrocytoma	IDH1 mutation + BRAF V600E	Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Pancreatic Adenocarcinoma	BRAF V600E	Pancreatic Adenocarcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Ampulla of Vater Carcinoma	BRAF V600E	Ampulla of Vater Carcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Salivary Gland Cancer	BRAF V600E	Salivary Gland Cancer	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2

Tafinlar (dabrafenib)

Associations
(201)

Associations
(201)

Tafinlar (dabrafenib)

Associations(201)

Associations(201)

Associations
(201)

Associations
(201)